TOP TEN perturbations for 40032_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40032_at
Selected probe(set): 205284_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40032_at (205284_at) across 6674 perturbations tested by GENEVESTIGATOR:
epigallocatechin gallate study 1 (45840ng/ml) / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-3.0042439Number of Samples:3 / 17
Experimental | epigallocatechin gallate study 1 (45840ng/ml) |
Bronchial epithelial cells (NHBE) treated with epigallocatechin gallate (45840ng/ml; vendor: Santa Cruz / catalog number: sc-200802 / catalog name: (-)-Epigallocatechin Gallate) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:--- | |
Control | vehicle (DME) treated bronchial epithelial cell sample |
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.6839647Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):2.3457603Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.333952Number of Samples:4 / 4
Experimental | R547 study 3 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):2.2727518Number of Samples:8 / 8
Experimental | PMA; ionomycine study 2 |
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
Control | unstimulated CD4 memory T-cell sample |
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):2.1858387Number of Samples:24 / 3
Experimental | colorectal cancer study 4 (recurring) |
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
Control | adjacent colon tissue (recurring) |
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.1388197Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):2.108533Number of Samples:2 / 2
Experimental | T-cell activation study 3 |
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
Control | resting CD4 T-lymphocyte (crude fraction) sample |
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.1029415Number of Samples:4 / 4
Experimental | R547 study 1 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
CH5183284 study 1 (HSC-39) / vehicle (DMSO) treated HSC-39 cell sample
Relative Expression (log2-ratio):-2.1017494Number of Samples:2 / 2
Experimental | CH5183284 study 1 (HSC-39) |
Human gastric cell line HSC-39 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:--- | |
Control | vehicle (DMSO) treated HSC-39 cell sample |
Human gastric cell line HSC-39 treated with 0.1% DMSO for 24 hours. |